Eli Lilly Acquires Struggling Biotech Kelonia for $3.25 Billion

From Near Collapse to Billion-Dollar Buyout

In one of biotech's most dramatic turnarounds, Kelonia Therapeutics has been acquired by Eli Lilly for $3.25 billion , marking an extraordinary conclusion to what venture capitalist Bryan Roberts describes as a "tortuous ride." Three times, the company came within a week of running out of cash , yet somehow managed to develop groundbreaking cancer treatment technology that caught the attention of one of the world's largest pharmaceutical companies.

The acquisition is a boon for the small startup, which has subsisted on $60 million over the last five years and previously struggled to stay afloat . Eli Lilly will acquire the privately-held, clinical-stage biotechnology company for up to $7 billion in cash, consisting of $3.25 billion upfront and $3.75 billion in milestones . The deal represents a staggering premium over the company's most recent valuation that stood marginally above $100 million in 2022 .

Following the announcement of Lilly's acquisition, Roberts shared these anecdotes along with the original investment memo and slide deck once used to get Kelonia — then called Elcano Therapeutics — off the ground . Kelonia was incubated and seed funded by Venrock , which believed in the company's potential despite its financial struggles.

Revolutionary Cancer Treatment Technology

Kelonia has developed a proprietary in vivo gene placement system (iGPS®) that uses specially engineered lentiviral-based particles designed to efficiently and selectively enter T-cells inside the body . This breakthrough allows doctors to reprogram a patient's immune cells to fight cancer without the complex, expensive process currently required for CAR-T therapies.

Current treatments require that work to be done outside the body, or ex vivo, a process that involves harvesting cells, engineering them in a lab and then reintroducing them . "Autologous CAR-T therapies have meaningfully improved outcomes for patients with various cancers, but significant manufacturing, safety, and access barriers mean that only a fraction of eligible patients actually receive them" , explained Jacob Van Naarden, Lilly's executive vice president of oncology.

The acquisition provides Eli Lilly with access to Kelonia's proprietary in vivo gene placement system platform and its lead program KLN-1010, a potentially first-in-class in vivo BCMA-targeting CAR-T therapy for relapsed/refractory multiple myeloma currently in Phase 1 development . KLN-1010 showed a 100% overall response rate in data presented at ASH 2025 .

Lilly's Aggressive Expansion Strategy

Lilly has been on a deal-making spree this year, announcing several acquisitions like sleep disorder drug developer Centessa Pharmaceuticals and cell therapy company Orna Therapeutics . In February, Lilly announced plans to purchase Watertown biotech Orna Therapeutics for up to $2.4 billion. A month later, Lilly announced it would acquire Centessa Pharmaceuticals, a narcolepsy drug maker with its US headquarters in Boston, in a deal worth about $6.3 billion .

Lilly has been bringing in record revenue from its weight-loss medicines, but continues to diversify its pipeline candidates through acquisitions of biotech companies that are developing new genetic therapies for cancer and other disorders . Van Naarden said the deals are all part of Lilly's plan to grow beyond the GLP-1 drugs for obesity and diabetes that Lilly is best known for .

Even factoring in the deals Lilly has already done, when asked if there could be more ahead, Van Naarden said, "We don't feel constrained" . The pharmaceutical giant appears determined to establish itself as a major player across multiple therapeutic areas, using its massive cash reserves from successful weight-loss drugs to fuel an acquisition strategy that could reshape cancer treatment accessibility.

Transforming Cancer Care Access

"Kelonia's in vivo platform has the potential to change that by delivering rapid, durable responses in a far simpler, off-the-shelf format" , Van Naarden noted. This technology could democratize access to advanced cancer treatments that are currently limited to specialized medical centers with sophisticated manufacturing capabilities.

Outside of multiple myeloma, Lilly plans to use Kelonia's technology to treat other blood cancers, and possibly solid tumors. "We're going to be a player in hematology" , Van Naarden declared. The acquisition positions Lilly to offer treatments that could reach patients in community hospitals rather than being confined to academic medical centers.

Kelonia's journey from near-bankruptcy to a multi-billion